Your Health, We Care

Home >Drug List>Lazertinib
  • Lazertinib
  • Lazertinib

Lazertinib(LuciLazer)

Another NameLeclaza, 拉泽替尼, 兰泽替尼

IndicationsIt is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 19 deletion

Specs

  • 80mg*60 tabs
  • Reg No.03 L 1326/25
  • Inspection NO.535-25
  • Dosage Formtablet
  • Indate24 months
  • Get in touch for a free consultation
  • WhatsApp

    Telegram name: Vira

  • Name: LUCIUS

    No.:0085253923643

Warm tips:Please purchase and use the medication under pharmacist guidance as the outer packaging is for reference only and the information is intended for professionals.
Introduction of Lazertinib

Lazertinib from Lucius Pharmaceuticals is a highly effective and well-tolerated oral kinase inhibitor. The combination therapy has demonstrated significant survival benefits in clinical studies, providing patients with a more valuable treatment option.

Medicine-related columns

Instructions of Lazertinib

Lucius Related Certificates

150-Lazertinib Test Report_proc.jpg

Drug Test Report

03L1326_25 Lazertinib Approval_proc.jpg

Drug Approval Certificate

Active Ingredient

The main active ingredient is lazertinib mesylate monohydrate.

Indicated Population

It is indicated for adult patients with advanced non-small cell lung cancer (NSCLC) whose EGFR mutations have been confirmed by an FDA-approved test.

Dosage and Administration

The recommended dose is 240 mg orally once daily, which can be taken with or without food, and must be used in combination with amivantamab.

Medication Use in Special Populations

Patients of childbearing potential must use effective contraceptive measures.

Use during lactation is not recommended.

No dosage adjustment is required for elderly patients or those with mild to moderate hepatic or renal impairment.

Drug Overdose

There is currently no specific antidote for overdose. Symptomatic and supportive treatment should be administered in case of drug overdose.

Storage Conditions

Store at room temperature between 20°C and 25°C; short-term storage within the range of 15°C to 30°C is permitted.

Pharmacokinetics

Lazertinib reaches peak plasma concentration 2–4 hours after oral administration, has a half-life of approximately 3.7 days, and is mainly excreted via feces.

FDA,2024.08